News - Zetia, Analgesia

Filter

Current filters:

ZetiaAnalgesia

Popular Filters

Executive Q&A: Bob Radie, chief executive and president of Egalet

Executive Q&A: Bob Radie, chief executive and president of Egalet

11-04-2014

In an interview with The Pharma Letter, Egalet Corporation’s chief executive Bob Radie discusses the…

AnalgesiaChemistryChief executiveCombination productsEgalet CorpEgalet CorporationInterviewsPharmaceuticalSevere chronic painUSA

Study: Half of veterans prescribed medical opioids continue to use them chronically

Study: Half of veterans prescribed medical opioids continue to use them chronically

07-03-2014

A study of nearly 1 million veterans who receive opioids to treat painful conditions found that more…

AnalgesiaHealthcarePharmaceuticalResearchUSA

High potency statins linked to better outcome following a heart attack

21-02-2014

A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment…

Cardio-vascularezetimibeMerck & CoPharmaceuticalResearchZetia

FDA says Durect’s pain relief drug Posidur needs additional safety studies

FDA says Durect’s pain relief drug Posidur needs additional safety studies

13-02-2014

US drugmaker Durect Corp says that the US Food and Drug Administration has issued a Complete Response…

AnalgesiaDurectPharmaceuticalPosidurRegulationUSA

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

24-01-2014

USA-based Amgen yesterday revealed positive results from the Phase III GAUSS-2 (Goal Achievement After…

AmgenBiotechnologyCardio-vascularevolocumabResearchZetia

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins

13-11-2013

New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

Altus signs $4 million agreement with Zogenix to license Zohydro ER

04-11-2013

Altus Pharmaceuticals has entered into an agreement with Zogenix to develop abuse deterrent formulations…

AnalgesiaLicensingNorth AmericaPharmaceuticalZogenixZohydro

Orexo’s Zubsolv could take market share from Suboxone, report suggests

Orexo’s Zubsolv could take market share from Suboxone, report suggests

30-10-2013

Edison Equity Research analysts say that expected new clinical data from Swedish drug developer Orexo…

AnalgesiaFinancialMarkets & MarketingNorth AmericaOrexo ABPharmaceuticalReckitt BenckiserZubsolv

Zogenix shares leap after FDA approval for Zohydro ER

Zogenix shares leap after FDA approval for Zohydro ER

28-10-2013

Shares of Zogenix rocketed on Friday after the US Food and Drug Administration approved Zohydro ER extended-release…

AnalgesiaNorth AmericaPharmaceuticalRegulationZogenixZohydro

FDA calls for reclassification of codeine combo medications to stricter schedules

FDA calls for reclassification of codeine combo medications to stricter schedules

25-10-2013

The US Food and Drug Administration has indicated that it wants to see the classification of codeine-containing…

AnalgesiaHydrocodone Bitartrate and AcetaminophenNorth AmericaPharmaceuticalRegulation

Pfizer to continue Remoxy pain relief development

Pfizer to continue Remoxy pain relief development

24-10-2013

US pharma giant Pfizer will continue the development program for Remoxy Extended-Release Capsules CII,…

AnalgesiaNorth AmericaPfizerPharmaceuticalRemoxyResearch

Iroko’s pain relief drug effective at low doses

Iroko’s pain relief drug effective at low doses

22-10-2013

Iroko Pharmaceuticals has announced that the US Food and Drug Administration has approved Zorvolex capsules…

AnalgesiaIrokoNorth AmericaPharmaceuticalRegulationZorvolex

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

21-10-2013

Pfizer has announced mixed results from two Phase IIIb studies of Lyrica capsules CV in patients with…

AnalgesiaLyricaNorth AmericaPfizerPharmaceuticalResearch

UK’s medicines watchdog recalls five Wockhardt medicines

UK’s medicines watchdog recalls five Wockhardt medicines

18-10-2013

The UK’s Medicines and Healthcare products Regulatory Agency has recalled five medicines made by Indian…

AnalgesiaDiabetesEuropeGliclazidePharmaceuticalProductionRegulationWockhardt

Merck & Co records loss in 2nd quarter as Singulair drops 80%

30-07-2013

US pharma giant Merck & Co (NYSE: MRK) has released second quarter results showing that worldwide sales…

FinancialGardasilIsentressJanumetJanuviaMerck & CoNorth AmericaPharmaceuticalRemicadeSimponi ARIASingulairVytorinZetia

Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute

30-04-2012

US drug giant Merck & Co sales that global sales in the first-quarter of 2012 increased 1% to $11.7 billion,…

FinancialLegalMerck & CoMylan LaboratoriesNorth AmericaPatentsPharmaceuticalVytorinZetia

US FDA mixed views on Vytorin and Zetia

26-01-2012

US drug giant Merck & Co (NYSE: MRK) yesterday received Food and Drug Administration approval to update…

Cardio-vascularMerck & CoNephrology and HepatologyNorth AmericaPharmaceuticalRegulationVytorinZetia

Back to top